Here, we show that ARMed CAR T engineered to secrete anti-PD1 minibodies can improve anti-tumor function not only in systemically located tumors but also deliver sufficient Ab levels within the brain at the site of the tumor to rescue CAR T function in an orthotopic D270 xenograft CAR T-resistant mouse model. The gene discussed is PDCD1; the disease is neoplasm.